Amy Vander Woude, MD
Hematology & Oncology · Grand Rapids, MINPI 1427059781
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,671 of the $2,229 with a category attached, or 75.0%. 21 manufacturers reported payments, led by AstraZeneca at 42.6% of the total. Reporting peaked in 2023 at $1,046 and has fallen 85.7% since, to $150 in 2025.
Across 63 payments — averaging $35.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$949
- Array Biopharma Inc$224
- Merck$167
- Gilead$117
- Foundation Medicine, Inc.$112
- Sanofi$103
- plus $557 from 15 others
Across 117 payments — averaging $10,220 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1.1M
- Genentech, Inc.$116K
- Merck$10K
- Pfizer$10K
- Eli Lilly$561
What the payments were for
- Travel & lodging$51323%
- Food & beverage$1,67175%
- Education$452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $949 |
| Array Biopharma Inc | 11 | $224 |
| Merck | 6 | $167 |
| Gilead | 7 | $117 |
| Foundation Medicine, Inc. | 1 | $112 |
| Sanofi | 4 | $103 |
| Amgen | 1 | $91 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $72 |
| Novartis | 4 | $66 |
| E.r. Squibb & Sons, L.L.C. | 2 | $52 |
| AbbVie | 2 | $38 |
| Stemline Therapeutics Inc. | 1 | $36 |
| Bristol Myers Squibb | 2 | $32 |
| Pfizer | 2 | $30 |
| Kyowa Kirin, Inc. | 2 | $30 |
| Eisai Inc. | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Servier Pharmaceuticals LLC | 1 | $17 |
| Myovant Sciences Inc. | 1 | $17 |
| EMD Serono, Inc. | 1 | $15 |
| Exelixis Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,229 in reported general payments places this provider in the 55th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 172 | $2,621,395 |
| OrserduElacestrant Hcl | 26 | $548,138 |
| KisqaliRibociclib Succinate | 35 | $540,137 |
| VerzenioAbemaciclib | 22 | $333,914 |
| NeulastaPegfilgrastim | 21 | $132,888 |
| NyvepriaPegfilgrastim-Apgf | 23 | $87,552 |
| Exemestane | 125 | $30,035 |
| EliquisApixaban | 35 | $24,881 |
| ZarxioFilgrastim-Sndz | 12 | $24,300 |
| Anastrozole | 572 | $19,509 |
| Letrozole | 260 | $10,326 |
| XareltoRivaroxaban | 12 | $9,933 |
| Tamoxifen Citrate | 120 | $5,148 |
| Prochlorperazine Maleate | 79 | $1,064 |
| Alendronate Sodium | 44 | $767 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Nyvepria, Eliquis | $30 | $2,733,829230 claims |
| Stemline Therapeutics Inc.Orserdu | $36 | $548,13826 claims |
| NovartisKisqali | $66 | $540,13735 claims |
| AmgenNeulasta | $91 | $132,88821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Grand Rapids
- Sreenivasa ChandanaGrand Rapids$305K
- Nehal LakhaniGrand Rapids$13K
- Eric SantosGrand Rapids$11K
- Erin PettijohnGrand Rapids$10K
- Colin HardinGrand Rapids$10K
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Mohammad ChistiTroy$180K
- Gordon SrkalovicLansing$167K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.